Expressional and prognostic value of TREM1 in ovarian cancer: A comprehensive study based on bioinformatics and clinical analysis validation.

IF 3.3 3区 医学 Q2 ONCOLOGY
Caihong Tang, Dong Ye, Qiong He, Qionghua He, Wenkai Zhou, Liya Lin, Chao Jiang, Da Huang, Jianwei Zhou
{"title":"Expressional and prognostic value of TREM1 in ovarian cancer: A comprehensive study based on bioinformatics and clinical analysis validation.","authors":"Caihong Tang, Dong Ye, Qiong He, Qionghua He, Wenkai Zhou, Liya Lin, Chao Jiang, Da Huang, Jianwei Zhou","doi":"10.7150/jca.101152","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Triggering receptor expressed in myeloid cells-1 (TREM1) is an important regulator of innate and adaptive immunity, which can directly amplify an inflammatory response. Current studies have found the immunomodulatory role of TREM1 in tumor microenvironment. However, the role of TREM1 in ovarian cancer (OV) remains unclear. <b>Methods:</b> Based on TCGA and GEO database, we performed bioinformatics analysis to evaluate the expression profile of TREM1. Then, the prognostic value of TREM1 was determined through Kaplan-Meier survival analyses. GO and KEGG enrichment along with GSEA analyses were performed to identify potential biological functions of TREM1 based on the gene co-expression network. IHC and RT-qPCR on clinical samples were performed to validate our database-derived results. Additionally, ESTIMATE and CIBERSORT analyses were used to assess the correlation between TREM1 and tumor microenvironment. Finally, the expression, prognosis and immune regulation patterns of TREM1 in pan-cancer were further explored to validate the role of TREM1 as a biomarker. <b>Results:</b> The expression of TREM1 is abnormally high in OV than in normal tissues. Patients with high TREM1 expression were linked with poor overall survival (OS) and disease-free survival (DFS). Then, cox regression analysis and a nomogram indicated that TREM1 was an independent prognostic factor and proved the effective predictive performance in OV. Enrichment analysis showed that TREM1 was highly enriched in cancer-and immune-related pathways. Additionally, immune analysis revealed that TREM1 was robustly positively associated with tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) infiltrating. Moreover, pan-cancer analysis showed TREM1 was closely associated with prognosis and immune-related genes expression in various types of cancer. <b>Conclusions:</b> Through a systematic and comprehensive analysis, our study revealed that TREM1 could serve as a prognostic and immunological biomarker in ovarian cancer.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"16 2","pages":"577-589"},"PeriodicalIF":3.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685700/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.101152","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Triggering receptor expressed in myeloid cells-1 (TREM1) is an important regulator of innate and adaptive immunity, which can directly amplify an inflammatory response. Current studies have found the immunomodulatory role of TREM1 in tumor microenvironment. However, the role of TREM1 in ovarian cancer (OV) remains unclear. Methods: Based on TCGA and GEO database, we performed bioinformatics analysis to evaluate the expression profile of TREM1. Then, the prognostic value of TREM1 was determined through Kaplan-Meier survival analyses. GO and KEGG enrichment along with GSEA analyses were performed to identify potential biological functions of TREM1 based on the gene co-expression network. IHC and RT-qPCR on clinical samples were performed to validate our database-derived results. Additionally, ESTIMATE and CIBERSORT analyses were used to assess the correlation between TREM1 and tumor microenvironment. Finally, the expression, prognosis and immune regulation patterns of TREM1 in pan-cancer were further explored to validate the role of TREM1 as a biomarker. Results: The expression of TREM1 is abnormally high in OV than in normal tissues. Patients with high TREM1 expression were linked with poor overall survival (OS) and disease-free survival (DFS). Then, cox regression analysis and a nomogram indicated that TREM1 was an independent prognostic factor and proved the effective predictive performance in OV. Enrichment analysis showed that TREM1 was highly enriched in cancer-and immune-related pathways. Additionally, immune analysis revealed that TREM1 was robustly positively associated with tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) infiltrating. Moreover, pan-cancer analysis showed TREM1 was closely associated with prognosis and immune-related genes expression in various types of cancer. Conclusions: Through a systematic and comprehensive analysis, our study revealed that TREM1 could serve as a prognostic and immunological biomarker in ovarian cancer.

TREM1在卵巢癌中的表达和预后价值:基于生物信息学和临床分析验证的综合研究。
背景:髓系细胞中表达的触发受体-1(TREM1)是先天性免疫和适应性免疫的重要调节因子,可直接放大炎症反应。目前的研究发现,TREM1 在肿瘤微环境中具有免疫调节作用。然而,TREM1 在卵巢癌(OV)中的作用仍不清楚。研究方法基于 TCGA 和 GEO 数据库,我们进行了生物信息学分析,以评估 TREM1 的表达谱。然后,通过 Kaplan-Meier 生存分析确定 TREM1 的预后价值。根据基因共表达网络,进行了GO和KEGG富集以及GSEA分析,以确定TREM1的潜在生物学功能。对临床样本进行了 IHC 和 RT-qPCR,以验证数据库得出的结果。此外,我们还使用了ESTIMATE和CIBERSORT分析来评估TREM1与肿瘤微环境之间的相关性。最后,进一步探讨了 TREM1 在泛癌症中的表达、预后和免疫调节模式,以验证 TREM1 作为生物标记物的作用。研究结果与正常组织相比,TREM1在OV中的表达异常高。TREM1高表达的患者总生存期(OS)和无病生存期(DFS)较差。然后,考克斯回归分析和提名图显示,TREM1是一个独立的预后因素,并证明其对OV具有有效的预测作用。富集分析表明,TREM1在癌症和免疫相关通路中高度富集。此外,免疫分析表明,TREM1与肿瘤相关巨噬细胞(TAMs)和调节性T细胞(Tregs)的浸润呈稳健的正相关。此外,泛癌症分析表明,TREM1 与各种癌症的预后和免疫相关基因的表达密切相关。结论通过系统而全面的分析,我们的研究发现 TREM1 可作为卵巢癌的预后和免疫生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cancer
Journal of Cancer ONCOLOGY-
CiteScore
8.10
自引率
2.60%
发文量
333
审稿时长
12 weeks
期刊介绍: Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信